Retail prices of essential drugs in Brazil: an international comparison

Nóbrega, Otávio de Tolêdo; Marques, André Ricardo; Araújo, Ana Cleire Gomes de; Karnikowski, Margô Gomes de Oliveira; Naves, Janeth de Oliveira Silva; Silver, Lynn

doi:10.1590/s1020-49892007000700006

Cited by 27 publications

(28 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A study performed in Ghana found that 93% of patients did not comply with their antihypertensive treatment regimen, 96% of which reported high medicine prices as the reason for not complying [8]. Other studies investigating medicine pricing in general, including cardiovascular medicines, found that medicines were generally poorly available and highly priced [9-12]. …”

Section: Introductionmentioning

confidence: 99%

Availability, price and affordability of cardiovascular medicines: A comparison across 36 countries using WHO/HAI data

Mourik

Cameron

Ewen

et al. 2010

BMC Cardiovasc Disord

131

130

View full text Add to dashboard Cite

BackgroundThe global burden of cardiovascular disease (CVD) continues to rise. Successful treatment of CVD requires adequate pharmaceutical management. The aim was to examine the availability, pricing and affordability of cardiovascular medicines in developing countries using the standardized data collected according to the World Health Organization/Health Action International methodology.MethodsThe following medicines were included: atenolol, captopril, hydrochlorothiazide, losartan and nifedipine. Data from 36 countries were analyzed. Outcome measures were percentage availability, price ratios to international reference prices and number of day's wages needed by the lowest-paid unskilled government worker to purchase one month of chronic treatment. Patient prices were adjusted for inflation and purchasing power, procurement prices only for inflation. Data were analyzed for both generic and originator brand products and the public and private sector and summarized by World Bank Income Groups.ResultsFor all measures, there was great variability across surveys. The overall availability of cardiovascular medicines was poor (mean 26.3% in public sector, 57.3% private sector). Procurement prices were very competitive in some countries, whereas others consistently paid high prices. Patient prices were generally substantially higher than international references prices; some countries, however, performed well. Chronic treatment with anti-hypertensive medication cost more than one day's wages in many cases. In particular when monotherapy is insufficient, treatment became unaffordable.ConclusionsThe results of this study emphasize the need of focusing attention and financing on making chronic disease medicines accessible, in particular in the public sector. Several policy options are suggested to reach this goal.

show abstract

Section: Introductionmentioning

confidence: 99%

Availability, price and affordability of cardiovascular medicines: A comparison across 36 countries using WHO/HAI data

Mourik

Cameron

Ewen

et al. 2010

BMC Cardiovasc Disord

131

130

View full text Add to dashboard Cite

show abstract

“…O caso em estudo reforça, portanto, a tese de que o sistema de concessão de patentes atual, particularmente na área da inovação farmacêutica, está fora de equilíbrio, fornecendo recompensas financeiras excessivas aos detentores patentários, sobretudo das grandes empresas farmacêuticas. No Brasil, essa situação parece ser amplificada, com o preço médio de medicamentos sendo 1,9 vez o praticado na Suécia e 13,1 vezes o índice mundial 29 .…”

Section: Discussionunclassified

Impacto orçamentário da incorporação de medicamentos para tratamento em segunda linha do edema macular diabético no SUS sob a perspectiva da Secretaria de Estado de Saúde de Minas Gerais, Brasil

et al. 2019

View full text Add to dashboard Cite

Resumo: Os objetivos foram efetuar a análise do impacto orçamentário para a incorporação de segunda linha terapêutica com terapia antiangiogênica de aplicação intravítrea, para tratamento de edema macular diabético, no âmbito do Sistema Único de Saúde (SUS) em Minas Gerais, Brasil, discutindo sua viabilidade à luz do orçamento do estado. A análise do impacto orçamentário com método determinístico, segundo diretriz do Ministério da Saúde. Foram incluídos os pacientes com provável falha ao tratamento de primeira linha, num horizonte temporal de 5 anos para todas as tecnologias avaliadas. Incluíram-se na análise os medicamentos bevacizumabe (uso off-label), ranibizumabe e aflibercepte. As populações foram calculadas tanto por demanda aferida quanto por estimativa epidemiológica. Como análises de sensibilidade efetuaram-se: cenário com difusão de tecnologia mais lenta; cenário com a entrada de bevacizumabe e ranibizumabe biossimilares no mercado; cenário com a desconsideração da inflação no período. O impacto orçamentário incremental, de acordo com as estimativas de demanda aferida e epidemiológica, respectivamente, foi de R$ 69.493.906,95-R$ 473.226.278,78 para bevacizumabe; R$ 349.319.965,60-R$ 2.378.732.103,09 para ranibizumabe e R$543.867.485,47-R$ 3.703.524.490,16 para aflibercepte. Bevacizumabe foi a alternativa financeiramente mais viável em todos os cenários das estimativas e análises de sensibilidade. Estimou-se incremento próximo a 3%, comparando com o orçamento de 2016 (demanda aferida). Avalia-se que a incorporação é viável dentro do SUS em Minas Gerais, mas sujeita às prioridades da gestão. A discrepância de preços entre produtos de eficácia semelhante é intrigante e tema fértil para estudos futuros.

show abstract

“…Almost after four decades, the first Brazilian EML was formulated; many research reported that EMs were moderately available in Brazilian public health facilities. [ 85 86 87 88 ] The up-to-date seventh edited version that was released in 2010 has more and more been included medicines and its formulations for pediatric use. [ 89 90 ] It has been reported that in general, the accessibility of EMs in the public health centers was 68.8%–81.7%.…”

Section: Aterials and M Ethodsmentioning

confidence: 99%

Essential medicine utilization and situation in selected ten developing countries: A compendious audit

Haque

2017

J Int Soc Prevent Communit Dent

View full text Add to dashboard Cite

Retail prices of essential drugs in Brazil: an international comparison

Cited by 27 publications

References 2 publications

Availability, price and affordability of cardiovascular medicines: A comparison across 36 countries using WHO/HAI data

Availability, price and affordability of cardiovascular medicines: A comparison across 36 countries using WHO/HAI data

Impacto orçamentário da incorporação de medicamentos para tratamento em segunda linha do edema macular diabético no SUS sob a perspectiva da Secretaria de Estado de Saúde de Minas Gerais, Brasil

Essential medicine utilization and situation in selected ten developing countries: A compendious audit

Contact Info

Product

Resources

About